Amicogen Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
7,575
7,513
2,538
1,903
3,575
Depreciation, Depletion & Amortization
982
1,283
2,417
5,275
7,398
Other Funds
-
-
3
-
-
Funds from Operations
10,209
10,223
4,343
7,763
9,091
Changes in Working Capital
3,586
5,798
7,999
3,514
2,791
Net Operating Cash Flow
6,623
4,426
12,343
11,277
11,882
Capital Expenditures
3,408
5,419
7,323
16,955
12,807
Sale of Fixed Assets & Businesses
2
119
21,648
1,103
18
Purchase/Sale of Investments
14,600
4,597
43,561
308
13,384
Net Investing Cash Flow
18,046
512
28,849
15,822
32,513
Cash Dividends Paid - Total
-
-
1,074
912
-
Issuance/Reduction of Debt, Net
3,337
140
6,292
954
2,129
Net Financing Cash Flow
12,664
923
27,750
1,866
20,639
Net Change in Cash
1,228
4,835
11,248
6,437
386
Free Cash Flow
3,801
177
6,536
2,549
433
Other Sources
45
902
388
361
2,460
Change in Capital Stock
16,001
1,062
35,119
-
18,511
Exchange Rate Effect
14
2
4
27
394
Other Uses
85
710
-
639
8,800

About Amicogen

View Profile
Address
64 Dongbu-ro 1259 beon-gil
Jinju SG 52621
Korea, Republic Of
Employees -
Website http://www.amicogen.com
Updated 09/14/2018
Amicogen, Inc. engages in the development and marketing of enzyme products and functional food materials. Its products include specialty enzyme for pharmaceutical, food, feed and industrial; new bio-ingredient such as natural health ingredients for food, feed and cosmetics, finished products; and immunological products such as protein A resin, anticancer treatment vaccine based on B cell and mononuclear cell, and POCT immune diagnosis device using innovative C-ECL technology. It also engages in original equipment manufacturing and original development manufacturing of nutraceutical products.